The use of the drug Elizaria – a biosimilar of the original eculizumab in atypical hemolytic-uremic syndrome due to mutation of the С3 gene in children: clinical observation and literature review

   This article presents the features of atypical haemolytic-uremic syndrome (ORPHA 544472) in children. Atypical haemolytic-uremic syndrome (aHUS) is defined by a triad: haemolytic anaemia, thrombocytopenia and acute kidney injury in pediatric and adult patients. The OMIM catalogue presents the phenotypic series of aHUS with mutations of the C3, CFB, CFH, CFHR1, CFHR3, DGKE, MCP, THBD genes. Atypical haemolytic-uremic syndrome is often associated with gene mutations in proteins and activators that regulate complement. We report the case of a girl who had a manifestation of aHUS at 8 years 5 months of age and a severe relapse at 8 years 10 months of age. The relapse was characterised by manifestations of haemolytic anaemia, thrombocytopenia, acute renal damage, severe arterial hypertension, high lactate dehydrogenase and membrane attack complex levels and low C3 component. After 5 courses of haemodialysis, 3 haemodiafiltration, diuresis increased and biochemical parameters improved. We presented with ASUS in a child associated with a p.Cys1101Tyr C3 gene mutation. We used a complement inhibitor, Elizaria®, a biosimilar to the original drug eculizumab, to treat a child with atypical haemolytic-uremic syndrome due to the C3 gene mutation. The complement system inhibitor therapy with Elizaria preserved the health and life of a sick girl with a severe relapse of aHUS.

1. OMIM (Online Mendelian Inheritance in Man) https://www.ncbi.nlm.nih.gov/omim/612925

2. https://www.orpha.net/consor/cgi-bin/index.php The portal for rare diseases and orphan drugs / https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=544472

3. Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Nephrology (Saint-Petersburg) 2012; 16 (2): 16–48 (In Russ.)

4. Clinical guidelines for HUS in children 2022 https://www.pediatr-russia.ru/information/klin-rek/deystvuyushchie-klinicheskie-rekomendatsii/%D0%93%D0%A3%D0%A1%20%D0%B4%D0%B5%D1%82%D0%B8%20%D0%A1%D0%9F%D0%A0.v2.pdf

5. Fremeaux-Bacchi V., Miller E. C., Liszewski M. K., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 49

6. Frémeaux-Bacchi V., Fakhouri F., Roumenina L. et al. Atypical hemolytic-uremic syndrome related to abnormalities within the complement system. Rev Med Interne 2011; 32 (4): 232–240. doi: 10.1016/j.revmed.2009.09.039

7. Siomou E., Gkoutsia A., Serbis A. et al. aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome. Pediatr Nephrol 2016; 31 (3): 513–517. doi: 10.1007/s00467-015-3267-3

8. Matsumoto T., Toyoda H., Amano K. et al. Clinical manifestation of patients with atypical hemolytic uremic syndrome with the C3 p.I1157T variation in the Kinki region of Japan. Clin Appl Thromb Hemost 2018; 24 (8): 1301–1307. doi: 10.1177/1076029618771750

9. Liu J., Xiao J., Chen L., Peng Y. Atypical hemolytic uremic syndrome with C3 mutation: A case report and literature review. Clin Nephrol 2021; 95 (3): 156–160. doi: 10.5414/CN110103.P

10. Toyoda H., Wada H., Miyata T. et al. Disease recurrence after early discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation. J Pediatr Hematol Oncol 2016; 38 (3): 137–139. doi: 10.1097/MPH.0000000000000505

11. Lumbreras J., Subias M., Espinosa N. et al. The relevance of the MCP risk polymorphism to the outcome of aHUS associated with C3 mutations. A case report. Front Immunol 2020; 16 (11): 1348. doi: 10.3389/fimmu.2020.01348

12. Saito D., Watanabe E., Ashida A. et al. Atypical hemolytic uremic syndrome with the p.ile1157thr c3 mutation successfully treated with plasma exchange and eculizumab: a case report. Crit Care Explor 2019; 1 (4): e0008. doi: 10.1097/CCE.0000000000000008

13. Mache C. J., Acham-Roschitz B., Frémeaux-Bacchi V. et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312–1316. doi: 10.2215/CJN.01090209

14. Köse O., Zimmerhackl L. B., Jungraithmayr T. et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36: 669–672. doi: 10.1055/s-0030-1262889

15. Al-Akash S. l., Almond P. S., Savell V. H. Jr. et al. Eculizumab induces long-term remission in recurrent post-transplantant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26: 613–619. doi: 10.1007/s00467-010-1708-6

16. Ptushkin V. V., Kulagin A. D., Lukina E. A. et al. Results of an openlabel Phase Ib multicenter clinical study evaluating the safety, pharmacokinetics and pharmacodynamics of the first eculizumab biosimilar in untreated patients with paroxysmal nocturnal hemoglobinuria in the induction phase of therapy. Ter. arh. 2020; 92 (7): 77–84 (In Russ.). doi: 10.26442/00403660.2020.07.000818

17. Kulagin A. D., Ptushkin V. V., Lukina E. A. et al. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol 2021, 100 (11): 2689–2698. doi: 10.1007/s00277-021-04624-7

18. Kulagin A. D., Ptushkin V. V., Lukina E. A. et al. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood 2019; 134 (Supp.1): 3748. doi: 10.1182/blood-2019-125693

19. Emirova Kh. M., Orlova O. M., Muzurov A. L. et al. Experience with the use of Elizaria® in atypical hemolytic-uremic syndrome. Pediatria n. a. G. N. Speransky 2019; 98 (5): 225–229 (In Russ.)

20. Lavrishcheva Yu. V., Yakovenko A. A., Kudlai D. A. Experience in the use of the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic uremic syndrome. Ter. arh. 2020; 92 (6): 76–80 (In Russ.). doi: 10.26442/00403660.2020.06.000649

21. Lavrishcheva I. V., Yakovenko A. A., Kudlay D. A. A case report of atypical hemolytic-uremic syndrome treatment with the first Russian eculizumab in adult patient. Urol Nephrol Open Access J 2020; 8 (2): 37–40. URL: https://medcraveonline.com/UNOAJ/a-case-report-of-atypical-hemolytic-uremic-syndrome-treatment-with-the-first-russian-eculizumab-in-adult-patient.html

22. Muff-Luett M., Sanderson K. R., Engen R. M. et al. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes – a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021; 36: 2349–2360. doi: 10.1007/s00467-021-04965-5

23. Pankov E. A., Papayan K. A., Kapustin S. I., Savenkova N. D. Features of the distribution of polymorphic variants of genes associated with thrombophilia and arterial hypertension in children with hemolyticuremic syndrome. Nephrology (Saint-Petersburg) 2020; 24 (3): 90–94 (In Russ.) doi: 10.36485/1561-6274-2020-24-3-90-94